Search Results - "Fröhling, S"

Refine Results
  1. 1

    Optimizing panel-based tumor mutational burden (TMB) measurement by Budczies, J., Allgäuer, M., Litchfield, K., Rempel, E., Christopoulos, P., Kazdal, D., Endris, V., Thomas, M., Fröhling, S., Peters, S., Swanton, C., Schirmacher, P., Stenzinger, A.

    Published in Annals of oncology (01-09-2019)
    “…Panel sequencing based estimates of tumor mutational burden (psTMB) are increasingly replacing whole exome sequencing (WES) tumor mutational burden as…”
    Get full text
    Journal Article
  2. 2

    Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia by Bochtler, T, Fröhling, S, Krämer, A

    Published in Leukemia (01-06-2015)
    “…Genetic abnormalities are a hallmark of cancer. Hereby, cytogenetic aberrations and small-scale abnormalities, such as single-nucleotide variations and…”
    Get full text
    Journal Article
  3. 3

    Biology-guided precision medicine in rare cancers: Lessons from sarcomas and neuroendocrine tumours by van der Graaf, W.T.A., Tesselaar, M.E.T., McVeigh, T.P., Oyen, W.J.G., Fröhling, S.

    Published in Seminars in cancer biology (01-09-2022)
    “…Rare cancers, which collectively account for almost 25 % of all malignancies, are poorly understood in terms of their aetiology and pathogenesis and are…”
    Get full text
    Journal Article
  4. 4

    Real‐world data for precision cancer medicine—A European perspective by Christopoulos, Petros, Schlenk, Richard, Kazdal, Daniel, Blasi, Miriam, Lennerz, Jochen, Shah, Rajiv, Budczies, Jan, Malek, Nisar, Fröhling, Stefan, Rosenquist, Richard, Schirmacher, Peter, Bozorgmehr, Farastuk, Kuon, Jonas, Reck, Martin, Thomas, Michael, Stenzinger, Albrecht

    Published in Genes chromosomes & cancer (01-09-2023)
    “…Leveraging real‐world data (RWD) for drug access is necessary to overcome a key challenge of modern precision oncology: tackling numerous low‐prevalence…”
    Get full text
    Journal Article
  5. 5

    RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia by Rudat, S., Pfaus, A., Cheng, Y. Y., Holtmann, J., Ellegast, J. M., Bühler, C., Marcantonio, D. Di, Martinez, E., Göllner, S., Wickenhauser, C., Müller-Tidow, C., Lutz, C., Bullinger, L., Milsom, M. D., Sykes, S. M., Fröhling, S., Scholl, C.

    Published in Leukemia (01-10-2018)
    “…Many cases of AML are associated with mutational activation of receptor tyrosine kinases (RTKs) such as FLT3. However, RTK inhibitors have limited clinical…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Radiotherapy in the treatment of aggressive fibromatosis: experience from a single institution by Seidensaal, K, Harrabi, S B, Weykamp, F, Herfarth, K, Welzel, T, Mechtersheimer, G, Lehner, B, Schneider, M, Fröhling, S, Egerer, G, Debus, J, Uhl, M

    Published in Radiation oncology (London, England) (05-06-2020)
    “…Desmoid-type fibromatosis is a rare, potentially locally aggressive disease. Herein we present our experience in the treatment with radiotherapy. In total 40…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10

    Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD) by Rempel, E., Kluck, K., Beck, S., Ourailidis, I., Kazdal, D., Neumann, O., Volckmar, A. L., Kirchner, M., Goldschmid, H., Pfarr, N., Weichert, W., Hübschmann, D., Fröhling, S., Sutter, C., Schaaf, C. P., Schirmacher, P., Endris, V., Stenzinger, A., Budczies, J.

    Published in NPJ precision oncology (09-06-2022)
    “…Homologous repair deficiency (HRD) is present in many cancer types at variable prevalence and can indicate response to platinum-based chemotherapy and PARP…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance by Rücker, F G, Russ, A C, Cocciardi, S, Kett, H, Schlenk, R F, Botzenhardt, U, Langer, C, Krauter, J, Fröhling, S, Schlegelberger, B, Ganser, A, Lichter, P, Zenz, T, Döhner, H, Döhner, K, Bullinger, L

    Published in Leukemia (01-02-2013)
    “…Recently, the p53-miR-34a network has been identified to have an important role in tumorigenesis. As in acute myeloid leukemia with complex karyotype (CK-AML)…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16

    Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial by SCHLENK, R. F, BENNER, A, GRIMMINGER, W, PREISS, J, HENSEL, M, FRÖHLING, S, DÖHNER, K, HAAS, R, DÖHNER, H, HARTMANN, F, DEL VALLE, F, WEBER, C, PRALLE, H, FISCHER, J. Th, GUNZER, U, PEZZUTTO, A, WEBER, W

    Published in Leukemia (01-08-2003)
    “…The objective of the AML HD93 treatment trial was to evaluate the outcome in young adults with acute myeloid leukemia (AML) after postremission therapy was…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19

    JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia by Zhou, C, Martinez, E, Di Marcantonio, D, Solanki-Patel, N, Aghayev, T, Peri, S, Ferraro, F, Skorski, T, Scholl, C, Fröhling, S, Balachandran, S, Wiest, D L, Sykes, S M

    Published in Leukemia (01-05-2017)
    “…The transcription factor JUN is frequently overexpressed in multiple genetic subtypes of acute myeloid leukemia (AML); however, the functional role of JUN in…”
    Get full text
    Journal Article
  20. 20

    PO-451 Targeted proteomics to improve therapy stratification of cancer patients by Wiemann, S, Wahjudi, L, Bernhardt, S, Abnaof, K, Richter, D, Hutter, B, Kreutzfeldt, S, Heining, C, Horak, P, Fröhling, S

    Published in ESMO open (01-07-2018)
    “…IntroductionThe heterogeneity of tumours calls for patient stratification to select the most effective, personalised therapies. The NCT MASTER (Molecularly…”
    Get full text
    Journal Article